u/nikhil_lindqvist

Same. Monthly is plenty at this stage and daily weighing made me miserable for no information gain.

Agreed — the itemised related substances table is the difference between a document and a receipt.

That is an accusation about a named individual and it does not belong here in any form.

intention to treat versus completers changes the number substantially

How long was the randomised phase before any extension?

FLOW was kidney outcomes and it is the one nobody quotes

regain is the expected outcome and framing it as failure helps nobody

UV at 214nm sees the peptide bond and picks up almost everything; at 280nm you are looking at aromatics only. Which wavelength the number came from is part of the number.

Watched heart rate on a wearable across twelve weeks because the threads said to.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.

Small fix — you have described interval stretching and called it a taper. The exposure profiles differ.

Stretching the interval, reducing the dose, or both?

Agreed — and appetite is the leading indicator. The scale is the lagging one.

ask for the storage condition the stability statement was written against

Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.

Net peptide content is the fraction of the powder that is actually peptide once counterion, water and residual solvent are accounted for.

This is the sentence to take away. The rest of the thread is footnotes to it.

ask for the mass spectrum, not just the purity number

research-use-only means not approved for human use, and here that covers everything

With a week-long half-life, exposure declines over several weeks after the last dose rather than stopping with it. The lag is why the first fortnight is uninformative.

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

axis labels included, always

Have you asked the supplier what they declare?

Asked the supplier what documentation travels with the shipment and got a straight answer. That was reassuring in itself.

Not convinced. Interval stretching changes your exposure profile, not just the total, and the two are not equivalent.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Correction: that study measured regain after discontinuation, not loss of effect during treatment. Very different findings.

That delay was at clearance, not with the carrier. The lane table separates them for exactly this reason.

chromatogram or it did not happen

the lot on the vial has to match the lot on the page

Correction: that is net peptide content, not purity. Different number, different meaning, and the document says so if you read the row label.

Been at maintenance for 2 months on 15mg. Nothing happens. That is the whole report and it took me a while to accept it as success.

a fortnight of nothing is not evidence that you are fine

This is the sentence that reframes the whole board. Appetite first, scale later.

Every claim I could trace in this board went back to about four papers. That was a sobering afternoon.

open-label extensions are not the same evidence as the randomised phase

Read a press release and the publication three months apart. The hedging in the second one was substantial.

Related substances itemised individually is a much stronger document than a single total, because it tells you the shape of the impurity profile rather than its size.

stopping abruptly and stopping gradually are different experiences

appetite returns before the scale acknowledges anything

Yes — the interval is the finding.

This is the distinction that would end about half the arguments on this board.

Pushing back a little: a missing field is usually presentation, not concealment. Ask for the full document before drawing conclusions.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.